We are live on ! Find out more
IMMX icon

Immix Biopharma
IMMX

12 hedge funds and large institutions have $406K invested in Immix Biopharma in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

71% more funds holding

Funds holding: 7 → 12 (+5)

0.83% more ownership

Funds ownership: 1.32% → 2.15% (+0.83%)

15% less capital invested

Capital invested by funds: $475K → $406K (-$69K)

Holders
12
Holders Change
+5
Holders Change %
+71.43%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$118K
2
Renaissance Technologies
Renaissance Technologies
New York
+$59.1K
3
Northern Trust
Northern Trust
Illinois
+$41.9K
4
UBS Group
UBS Group
Switzerland
+$16.8K
5
State Street
State Street
Massachusetts
+$9.62K

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$74
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$143K +$118K +54,220 +107%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$104K +$7.51K +3,436 +5%
State Street
3
State Street
Massachusetts
$58K +$9.62K +4,400 +11%
Renaissance Technologies
4
Renaissance Technologies
New York
$37K +$59.1K +27,050 New
Northern Trust
5
Northern Trust
Illinois
$26K +$41.9K +19,151 New
ICG
6
InterOcean Capital Group
Tennessee
$22K – – –
UBS Group
7
UBS Group
Switzerland
$16K +$16.8K +7,667 +177%
Wells Fargo
8
Wells Fargo
California
– -$74 -34 -49%
Morgan Stanley
9
Morgan Stanley
New York
– +$7 +3 New
Fidelity Investments
10
Fidelity Investments
Massachusetts
– +$20 +9 New
TRCT
11
Tower Research Capital (TRC)
New York
– +$546 +250 New

IMMX Hedge Fund Activity: Q3 2022 in Review

12 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q3 2022, worth a combined $406K — down 15% from $475K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new IMMX positions and 0 closed out — a net gain of 5 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, adding an estimated $118K. The largest seller was Wells Fargo, cutting an estimated $74.

  • 12 institutional investors held Immix Biopharma (IMMX) as of Q3 2022, up from 7 in Q2 2022.
  • Funds reported $406K of Immix Biopharma stock for Q3 2022, down 15% quarter-over-quarter.
  • 5 funds opened new Immix Biopharma positions in Q3 2022 and 0 closed out, a net change of +5 holders.
  • The largest Immix Biopharma buyer in Q3 2022 was Vanguard Group, an estimated $118K added.
  • The largest Immix Biopharma seller in Q3 2022 was Wells Fargo, an estimated $74 sold.

Based on aggregated 13F filings for Q3 2022.